Retrophin Reports Third Quarter 2020 Financial Results
05. November 2020 16:01 ET
|
Retrophin, Inc.
Pivotal DUPLEX Study of sparsentan in FSGS nears completion of enrollment; topline proteinuria data expected 1Q21 Pivotal PROTECT Study achieved enrollment of 280th patient with IgAN to enable...
Retrophin to Report Second Quarter 2020 Financial Results
16. Juli 2020 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, July 16, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2020 financial results on Thursday, July 30, 2020 after the close of the...
Retrophin Reports First Quarter 2020 Financial Results
11. Mai 2020 16:01 ET
|
Retrophin, Inc.
Enrollment continues in the pivotal DUPLEX and PROTECT studies of sparsentan DUPLEX Study of sparsentan in FSGS enrolled first 190 patients required for interim proteinuria analysis Net product...
Retrophin Reports Third Quarter 2019 Financial Results
30. Oktober 2019 16:01 ET
|
Retrophin, Inc.
Enrollment on-track in pivotal Phase 3 clinical trials to support registration of sparsentan for patients with FSGS and IgAN Third quarter revenues rose nine percent to $44 million ...
Retrophin Reports Fourth Quarter and Full Year 2018 Financial Results
26. Februar 2019 16:01 ET
|
Retrophin, Inc.
Top-line results from pivotal Phase 3 FORT Study in PKAN expected in 3Q 2019 Two pivotal Phase 3 studies of sparsentan progressing on-track to enable potential first-in-class treatment for both FSGS...
Retrophin to Report Fourth Quarter and Full Year 2018 Financial Results
12. Februar 2019 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report fourth quarter and full year 2018 financial results on Tuesday, February 26, 2019 after the...